Introduction
Systemic juvenile idiopathic arthritis (SJIA) is regarded as an autoinflammatory disease (AID) of unknown etiology related to abnormalities of the innate immune system. A major role in the pathogenesis has been ascribed to proinflammatory cytokines as interleukin (IL)-6 and IL-1.
Objectives
Analysis of treatment results with the IL-6 inhibitor tocilizumab
Patients and methods
From 7/2009 to 4/2014 200 patients with SJIA were documented in the AID-registry. 46 of 200 patients (19 m, 27 f) at the age of 1-18 years (median 9) received therapy with tocilizumab (median 13 months, range 1-48). 24 of 46 patients received long term treatment (median 23 months, range 12-48) and were evaluated concerning Wallace criteria [1] . Different clinical courses were continuous (C) n=12, polycyclic (PC) n=16, arthritic (A) n=18. Besides we estimated a response rate (definition: no clinical manifestation and no inflammation parameters) in the first 12 weeks of treatment. Data are based on the AID-Registry (http://www.aid-register.de).
Results
According to Kaplan-Meier analysis 30% reached inactive disease or remission after the first 12 weeks of treatment. A rapid response to tocilizumab seems to be related to long term inactivity of SJIA. Comparison of the three disease courses (PC, C, A) revealed significant differences in the outcome; polycyclic courses show the fastest response followed by continuous courses. Worst outcome was evaluated in arthritic courses. Wallace criteria measured after at least 12 months: remission 54%, active disease 25%, inactive disease 21%. 4 (9%) patients were non-responders over the whole time. 60% of the patients showed no measurable CRP within the first 4 weeks and during tocilizumab therapy. Adverse events were reported in 11 (24%) patients: most leukopenia, infections and elevated transaminases, one Hodgkin's lymphoma, one gut perforation.
Conclusion
A significant proportion of patients documented with SJIA in der German AID-registry is treated with tocilizumab (23%). We estimated a good response in the first 12 weeks of therapy of 30% and also by Wallace of 76% (inactive disease or remission). The response appears to depend on different disease phenotypes. 
